4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT1B/1D receptor agonist activity?

@article{Knight20014991W93IR,
  title={4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT1B/1D receptor agonist activity?},
  author={Y. Knight and L. Edvinsson and P. Goadsby},
  journal={Neuropharmacology},
  year={2001},
  volume={40},
  pages={520-525}
}
Calcitonin gene-related peptide (CGRP) is a marker for trigeminovascular activation and is released during the headache phase of migraine and cluster headache. CGRP may have a role in migraine through its potent cranial vasodilator effects, or by an action on trigeminal nerve activity, both of which are targeted by 5HT(1B/1D) agonist drugs. CP122,288, a conformationally restricted analogue of sumatriptan that is a potent inhibitor of neurogenic plasma protein extravasation (PPE), was… Expand
mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene–related peptide in the rat trigeminovascular system
TLDR
This study investigated the mRNA expression of these receptors and the role of 5‐HT1 receptor subtypes in controlling the release of calcitonin gene–related peptide (CGRP) in rat dura mater, trigeminal ganglion (TG), and trigemINAL nucleus caudalis (TNC) and found that sumatriptan reduced the iC GRP release via activation of 5-HT1D and 5‐ HT1F receptor sub types. Expand
Calcitonin Gene-Related Peptide Antagonists as Treatments of Migraine and Other Primary Headaches
TLDR
The prospect of a non-vasoconstricting therapy for acute migraine offers a real opportunity to patients, and perhaps more importantly, provides a therapeutic rationale to reinforce migraine as a neurological disorder. Expand
Adenosine A1 receptor agonists inhibit trigeminovascular nociceptive transmission.
TLDR
In this model of trigeminovascular nociception, adenosine A1 receptor activation leads to neuronal inhibition without concomitant vasoconstriction, suggesting a novel avenue for the treatment of migraine and cluster headache. Expand
Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review
TLDR
It remains an enigma how the observed increase of CGRP in the EJV fits into the mechanisms of migraine and cluster headache. Expand
Sumatriptan Causes Parallel Decrease in Plasma Calcitonin Gene-Related Peptide (CGRP) Concentration and Migraine Headache During Nitroglycerin Induced Migraine Attack
TLDR
Plasma C GRP concentration decreases parallel to headache intensity during sumatriptan treatment and this decrease in CGRP predicts effectiveness of antimigraine drug therapy, which supports that one of the main effects of triptans is to decrease CgrP release. Expand
New targets in the acute treatment of headache
  • P. Goadsby
  • Medicine
  • Current opinion in neurology
  • 2005
TLDR
The prospect of a non-vasoconstrictor acute migraine therapy offers a real opportunity to patients, and perhaps more importantly, provides a therapeutic rationale to plant migraine and cluster headache firmly in the brain as neurological problems. Expand
The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis
TLDR
This meta-analysis suggests that CGRP-mAbs are effective in anti-migraine therapy with few adverse reactions, but more and larger sample-size RCTs are required to verify the current findings. Expand
Intrathecal dihydroergotamine inhibits capsaicin-induced vasodilatation in the canine external carotid circulation via GR127935- and rauwolscine-sensitive receptors.
TLDR
Intrathecal dihydroergotamine seems to inhibit the external carotid vasodilatation to capsaicin by spinal activation of serotonin 5-HT(1B/1D) (probably 5- HT( 1B)) receptors and α(2) ( probably α( 2A/2C))-adrenoceptors. Expand
Post-triptan era for the treatment of acute migraine
  • P. Goadsby
  • Medicine
  • Current pain and headache reports
  • 2004
TLDR
A number of targets are reviewed in this article including serotonin 5- HT1F and 5-HT1D receptors, adenosine A1 receptors, nociceptin, vanilloid TRPV1 receptors and anandamide CB1 receptors. Expand
Recent advances in understanding migraine mechanisms, molecules and therapeutics.
  • P. Goadsby
  • Medicine
  • Trends in molecular medicine
  • 2007
TLDR
Brain imaging studies have firmly established reproducible changes in the brainstem in regions that include areas that are involved in sensory modulation, leading to the view that migraine is a form of sensory dysmodulatio--a system failure of normal sensory processing. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 51 REFERENCES
Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288
TLDR
It is demonstrated that the potent inhibitor of PPE, CP122, 288, which has been shown in clinical trials to be ineffective in treating acute migraine attacks, had no effect on CGRP release, whereas the effective anti-migraine drug and relatively impotent inhibitor ofPPE, avitriptan, blocked C GRP release. Expand
hCGRP8-37, a calcitonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery.
TLDR
The C-terminal fragment of human calcitonin gene-related peptide, hCGRP8-37, fails to induce any biological activity in a variety of isolated tissues and behavioral assays even though it possesses nanomolar affinity for [125I]hC GRP alpha binding sites in the central nervous system and peripheral membrane preparations, which suggests the existence of at least two classes of CGRP receptors. Expand
Serotonin 5-HT1B/1D Receptor Agonists in Migraine
TLDR
Some aspects of the pharmacokinetics of the various triptans, such as the relationship between time to reach peak plasma concentrations and half-lives and clinical efficacy, may reveal information about the fundamental processes at work in acute migraine. Expand
Differential effects of low dose CP122,288 and eletriptan on Fos expression due to stimulation of the superior sagittal sinus in cat☆
TLDR
The data suggest that activation of the 5HT(1B/1D) receptor is important for the clinical action of this class of compounds and is consistent with the fact the CP122,288 is ineffective in the treatment of the acute attack of migraine. Expand
Differential Distribution of 5Ht1D-and 5HT1B-Immunoreactivity within the Human Trigemino-Cerebrovascular System: Implications for the Discovery of New Antimigraine Drugs
TLDR
A differential distribution of these receptor subtypes within the human trigemino-cerebrovascular system is demonstrated using 5HT1D- and5HT1B-receptor-specific antibodies and has important implications for the design of new antimigraine drugs. Expand
Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine ?
TLDR
It is demonstrated that systemically administered zolmitriptan can inhibit evoked trigeminovascular activity within the trigeminal nucleus, which may play a role in the anti‐migraine actions of this compound and offers the prospect of a third pathophysiologically consistent target site for anti‐Migraine drug effects. Expand
Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c‐fos in the caudal trigeminal nucleus in an experimental migraine model
The supratentorial cerebral dura of the albino rat is equipped with a rich sensory innervation including nociceptive axons and their terminals, which display intense calcitonin gene‐related peptideExpand
The calcitonin gene-related peptide antagonist CGRP8–37 increases the latency to withdrawal responses bilaterally in rats with unilateral experimental mononeuropathy, an effect reversed by naloxone
TLDR
The decrease in reflex responsiveness induced by calcitonin gene-related peptide (8-37) was counteracted by naloxone, indicating that opioids control the net effect of excitation in the spinal cord circuitry induced by calcium-based peptide and possibly other co-released neurotransmitters. Expand
Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion
TLDR
Drug-induced attenuation of levels of CGRP in plasma may reflect inhibition of release, to provide evidence to explain blockade of neurogenic extravasation of plasma. Expand
Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack
TLDR
The augmented levels of CGRP‐LI measured before and after nitroglycerin administration, when the provoked attack reached the maximum intensity, suggest an activation of the trigeminovascular system during the active period of cluster headache. Expand
...
1
2
3
4
5
...